Overview


According to FutureWise analysis, the market for Acute Repetitive Seizures is estimated to grow at a CAGR of 48% over the forecast period of 2023-2031.

Acute repetitive seizures, more commonly known as cluster, crescendo, or sequential seizures, are outbreaks of increased seizure activity occurring in individuals with refractory epilepsy who are already receiving a stable protocol of anticonvulsants. They lie in the seizure spectrum between isolated seizures and status epilepticus. If acute repetitive seizures are left untreated, they may progress to status epilepticus. Acute repetitive seizures are rated a neurological emergency, and treatment must be prompt. The primary goals of therapy are cessation of the seizure and prevention of recurrence. The use of traditional intravenous agents such as phenytoin, phenobarbital, lorazepam, and diazepam is well-established in the first-line treatment of acute seizures. However, adverse effects and the time to onset of effect often dictate the choice between older anticonvulsants. Newer agents and alternative routes of administration have been developed to reduce adverse effects, decrease the time to onset of effect, reduce acute care facility costs and investigate the possibility of home treatment.

Treatment should only be administered by caregivers in the opinion of the prescriber and are capable of monitoring the clinical response. Caregivers should possess confidence in their ability to identify the appropriate timing and method of treatment. The prescriber and caregiver should have a documented plan on when to treat and what to observe and post-treatment actions . The most immediate treatment for out-of-hospital care and the only U.S. FDA-approved product for acute repetitive seizures is rectal diazepam gel administered within a range of 0.2 to 0.5 mg/kg, based on age and weight. Treatment may lead to a state of central nervous system depression.

FutureWise Market Research has published a report that provides an insightful analysis acute repetitive seizures market trends that are affecting the overall market growth. This report will provide a detailed analysis of market share, regional insights, and competitor analysis that includes stature of key manufacturers operational in this industry.

According to the analysis conducted by FutureWise research analysts, acute repetitive seizures market is estimated to register a considerable growth rate over the forecast period. This report lists the market segments and potential prospects available across this industry, in addition providing crucial information on the total valuation currently held by the industry. Moreover, this report will assist key management individuals in an organisation to enhance their decisions pertaining to business expansion as well as strategic changes for increasing customer base.

  • Valeant Pharmaceuticals
  • Alexza Pharmaceuticals
  • Veriton Pharma Limited
  • Sanofi
  • Pfizer Inc.
  • Neurelis
  • UCB S.A
  • Acorda Therapeutics, Inc.
  • Upsher-Smith Laboratories, LLC
  • Epalex

(Note: The list of the major players will be updated with the latest market scenario and trends)

The rising prevalence of epilepsy due to genetic inclination, brain injuries, and stroke is expected to anticipate the acute repetitive seizures market growth. Acute repetitive seizures, commonly associated with epilepsy, have increased the demand for effective treatment options. Significant factors influencing the market expansion are the emergence of novel routes of administration for epileptic seizures, along with advancements in drug treatments. Additionally, research on genetic factors related to brain malformations and epileptic seizures has provided valuable insights, further stimulating the development of targeted therapies. Moreover, the collaboration between pharmaceutical companies and research institutions for R&D offers a great opportunity for the market to bring innovative and effective treatments for acute repetitive seizures and other forms of epilepsy. Moreover, the notable trend toward the widespread use of generic medicines experienced significant growth in the market. Oral benzodiazepines such as diazepam and lorazepam have emerged as dominant players in this condition. These medications are preferred for their well-established effectiveness and relatively low cost compared to brand-name alternatives. Furthermore, the lack of knowledge of seizures and several unfavorable factors significantly impact the acute repetitive seizures market growth. The lack of access to proper healthcare services, high-cost treatment options, and unavailability of emergency treatment are some factors hindering the market growth. Moreover, patients prefer the nasal administration over other pharmaceutical administration routes, such as buccal, rectal, and intramuscular. Outpatient treatment with parenteral drugs is the best treatment option.

By Drug Class

  • Benzodiazepines
    • lorazepam
    • Diazepam
    • Midazolam

By Route of Administration

  • Oral
  • Intramuscular
  • Intranasal
  • Buccal
  • Rectal

By Distribution channel

  • Hospitals
  • Specialty Clinic pharmacies
  • Online stores

By Region

  • North America
  • Europe
  • Asia-Pacific
  • Latin America
  • Middle East and Africa

This market research report also emphasis on factors affecting the growth rate in various regions listed above. A deep-down analysis of region will also be provided in the final version of this market which is based on conclusion of primary interviews and secondary data point gathered during the process.

By region, the market is segmented into North America, Latin America, Europe, Asia-Pacific, and Middle East & Africa. North America registered highest share in the market in 2022. Due to the  presence of a significant target group for epilepsy drugs is primarily responsible for revenue growth in the acute repetitive seizures market share in the United States. Also, this growth is credible to escalation in neurological disorders, surge in brain injuries, current drug approvals, and well-established healthcare infrastructure. North America is likely to propel the growth of the acute repetitive seizures market during the forecast period.

  • Tier 1 players- established companies in the market with a major market share
  • Tier 2 players
  • Emerging players which are growing rapidly
  • New Entrants

  • Growth prospects
  • SWOT analysis
  • Key trends
  • Key data-points affecting market growth

  • To provide with an exhaustive analysis on the Acute Repetitive Seizures Market By Drug Class, By Route of Administration, By Distribution Channel and By Region.
  • To cater comprehensive insights on factors such as drivers, restraints, trends, opportunity, and additionally segmental and regional factors impacting market growth.
  • To evaluate current market trends and forecast micro-markets and the overall market projections which are represented in the format of data-sets and ppt.
  • To predict the market size, in key regions— North America, Europe, Asia Pacific, Latin America and Middle East and Africa. 
  • To provide information on competitors which includes landscape mapping, technological advancements, R&D spending, news concerning strategic alliances, and new product launches

  • We have a flexible delivery model and you can suggest changes in the scope/table of content as per your requirement
  • The customization Mobility Care offered are free of charge with purchase of any license of the report
  • You can directly share your requirements/changes to the current table of content to: sales@futurewiseresearch.com

Table of Contents


  • 1.   Market Introduction
    •   1. Objectives of the Study
        2. Market Definition
        3. Market Scope
         3.1. Years Considered for the Study
         3.2. Market Covered
        4. Currency
        5. Limitations
        6. Stakeholders
  • 2.   Research Methodology
    •   1. Research Data
         1.1. Secondary Data
          1.1.1. Key Data from Secondary Sources
         1.2. Primary Data
          1.2.1. Key Data from Primary Sources
        2. Market Size Estimation
        3. Market Breakdown and Data Triangulation
        4. Assumptions for the Study
  • 3.   Executive Summary
    •   1. Market Outlook
        2. Segment Outlook
        3. Competitive Insights
  • 4.   Acute Repetitive Seizures Market Variables, Trends and Scope
    •   1. Market Lineage Outlook
        2. Penetration and Growth Prospect Mapping
        3. Industry Value Chain Analysis
        4. Cost Analysis Breakdown
        5. Technology Overview
        6. Regulatory Framework
         6.1. Reimbursement Framework
         6.2. Standards and Compliances

  • 5.   Market Overview
    •   1. Market Dynamics
         1.1. Market Driver Analysis
          1.1.1. Increasing focus of Acute Repetitive Seizures Market Companies on Brand Protection
          1.1.2. Untapped Opportunities in Emerging Regions
         1.2. Market Restraint Analysis
          1.2.1. High Cost Associated with Implementation of Predictive Analysis
         1.3. Industry Challenges
          1.3.1. Presence of Ambiguous Regulatory Framework
  • 6.   Acute Repetitive Seizures Market Analysis Tools
    •   1. Industry Analysis - Porter’s
         1.1. Supplier Power
         1.2. Buyer Power
         1.3. Substitution Threat
         1.4. Threat from New Entrants
         1.5. Competitive Rivalry
        2. Pestel Analysis
         2.1. Political Landscape
         2.2. Environmental Landscape
         2.3. Social Landscape
         2.4. Technology Landscape
         2.5. Legal Landscape
        3. Major Deals And Strategic Alliances Analysis
         3.1. Joint Ventures
         3.2. Mergers and Acquisitions
         3.3. Licensing and Partnership
         3.4. Technology Collaborations
         3.5. Strategic Divestments
        4. Market Entry Strategies
        5. Case Studies
  • 7.   Acute Repetitive Seizures Market, By Drug Class Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Benzodiazepines
         1.1. lorazepam
         1.2. diazepam
         1.3. midazolam

  • 8.   Acute Repetitive Seizures Market, By Route of Administration Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Oral
        2. Intramuscular
        3. Intranasal
        4. Buccal
        5. Rectal

  • 9.   Acute Repetitive Seizures Market, By Distribution channel Historical Analysis and Forecast 2023-2031 (USD Million)
    •   1. Hospitals
        2. Specialty Clinic pharmacies
        3. Online stores

  • 10.   North America Acute Repetitive Seizures Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. U.S.A
         2.2. Canada
         2.3. Mexico
        3. Market Size (USD Million) Forecast for North America 2023-2031

  • 11.   Latin America Acute Repetitive Seizures Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Brazil
         2.2. Venezuela
         2.3. Argentina
         2.4. Rest of Latin America
        3. Market Size (USD Million) Forecast for Latin America 2023-2031

  • 12.   Europe Acute Repetitive Seizures Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Germany
         2.2. U.K
         2.3. France
         2.4. Italy
         2.5. Spain
         2.6. Russia
         2.7. Poland
         2.8. Rest of Europe
        3. Market Size (USD Million) Forecast for Europe 2023-2031

  • 13.   Asia Pacific Acute Repetitive Seizures Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. Japan
         2.2. China
         2.3. India
         2.4. Australia and New Zealand
         2.5. ASEAN
         2.6. Rest of Asia Pacific
        3. Market Size (USD Million) Forecast for Asia Pacific 2023-2031

  • 14.   Middle East and Africa Acute Repetitive Seizures Market Analysis 2017-2022 and Forecast 2023-2031 (USD Million)
    •   1. Introduction
        2. Historical Market Size (USD Million) Analysis By Country, 2017-2022
         2.1. GCC
         2.2. Israel
         2.3. South Africa
         2.4. Rest of MEA
        3. Market Size (USD Million) Forecast for MEA 2023-2031

  • 15.   Market Share Analysis and Competitive Landscape
    •   1. Global Landscape - Key Players, Revenue and Presence
        2. Global Share Analysis - Key Players (Tier 1, Tier 2, Tier 3)
        3. Global Emerging Companies
        4. North America - Market Share Analysis and Key Regional Players
        5. Europe - Market Share Analysis and Key Regional Players
        6. Asia Pacific - Market Share Analysis and Key Regional Players
        7. Global Key Player - Growth Matrix
  • 16.   Company Profiles (Competition Dashboard, Competitors Deep Dive, Products Offered and Financial Layouts)
    •   1. Valeant Pharmaceuticals
         1.1. Company Overview
         1.2. Product Portfolio
         1.3. SWOT Analysis
         1.4. Financial Overview
         1.5. Strategic Overview
        2. Alexza Pharmaceuticals
         2.1. Company Overview
         2.2. Product Portfolio
         2.3. SWOT Analysis
         2.4. Financial Overview
         2.5. Strategic Overview
        3. Veriton Pharma Limited
         3.1. Company Overview
         3.2. Product Portfolio
         3.3. SWOT Analysis
         3.4. Financial Overview
         3.5. Strategic Overview
        4. Sanofi
         4.1. Company Overview
         4.2. Product Portfolio
         4.3. SWOT Analysis
         4.4. Financial Overview
         4.5. Strategic Overview
        5. Pfizer Inc.
         5.1. Company Overview
         5.2. Product Portfolio
         5.3. SWOT Analysis
         5.4. Financial Overview
         5.5. Strategic Overview
        6. Neurelis
         6.1. Company Overview
         6.2. Product Portfolio
         6.3. SWOT Analysis
         6.4. Financial Overview
         6.5. Strategic Overview
        7. UCB S.A
         7.1. Company Overview
         7.2. Product Portfolio
         7.3. SWOT Analysis
         7.4. Financial Overview
         7.5. Strategic Overview
        8. Acorda Therapeutics, Inc.
         8.1. Company Overview
         8.2. Product Portfolio
         8.3. SWOT Analysis
         8.4. Financial Overview
         8.5. Strategic Overview
        9. Upsher-Smith Laboratories, LLC
         9.1. Company Overview
         9.2. Product Portfolio
         9.3. SWOT Analysis
         9.4. Financial Overview
         9.5. Strategic Overview
        10. Epalex
         10.1. Company Overview
         10.2. Product Portfolio
         10.3. SWOT Analysis
         10.4. Financial Overview
         10.5. Strategic Overview

  • 17.   Pre and Post COVID-19 Impact
    •   1. Positive influence on the healthcare industry
        2. The financial disruption of the manufacturing sector
        3. Impact of COVID-19 on emerging companies
        4. Significant mandates in the regulations initiated by healthcare administrations
        5. The overall economic slowdown of the developing and developed nations
  • 18.   FutureWise SME Key Takeaway Points for Client

Related Market

Neonatal Seizures Drugs Market

Read More

Epileptic Seizures Treatment Market

Read More
Partner

Our Clients